Research programme: cancer therapeutics - CRT/BioFocus
Latest Information Update: 15 Apr 2014
At a glance
- Originator BioFocus DPI; Cancer Research Technology
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 31 Mar 2014 BioFocus DPI has been acquired by Charles River Laboratories
- 07 Apr 2003 No development reported - Preclinical for Cancer in United Kingdom (unspecified route)
- 04 Jul 2001 Cambridge Drug Discovery has been acquired by BioFocus